Navigation Links
Federal grant funds research on novel HIV therapy

An immunology researcher at The Children's Hospital of Philadelphia leads a multi-center $6.7 million program project grant recently awarded by the National Institute of Mental Health (NIMH) to explore a novel approach to HIV treatment.

Encompassing basic science research, animal studies and clinical trials in adult patients, the new grant focuses on a potential Achilles' heel in the human immunodeficiency virus: sites on immune cells known as neurokinin-1 receptors. In focusing on those sites, researchers hope to achieve a triple benefit: fighting HIV by blocking the virus from immune cells, improving innate immune function and reducing symptoms of depression that are associated with the disease.

Steven D. Douglas, M.D., professor of Pediatrics, chief of the Section of Immunology and director of Clinical Immunology Laboratories at The Children's Hospital of Philadelphia, is the principal investigator and program director of the new Integrated Preclinical/Clinical Program grant. Dr. Douglas oversees projects led by collaborators at four sites: Children's Hospital, the University of Pennsylvania, Tulane National Primate Research Center, and Seracare Bioservices, Inc.

The program project is entitled, "Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy." NIMH, a member institute of the National Institutes of Health, issued the four-year, $6.7 million grant award this fall.

The grant builds on more than a decade of investigation by Dr. Douglas into substance P, a neurotransmitter long known to be active in the brain and nervous system. Dr. Douglas and colleagues discovered in 1997 that immune cells produce substance P and its receptor, neurokinin-1, and later showed that incubation with substance P raised HIV levels in immune cell cultures. They subsequently found that a compound that binds to the substance P receptor in immune cells inhibits HIV from entering its hiding place within immune cells.

That compound, from a class
'"/>

Source:Children's Hospital of Philadelphia


Page: 1 2 3

Related biology news :

1. Federal testing for mad cow disease a failure, law review editor says
2. Researcher gets NSF grant to create mutant maize lines
3. MSU researchers receive $4 million grant to uncover gene functions
4. Virulizin granted orphan drug status in Europe
5. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
6. Asian immigrants in NYC not receiving HIV education at religious institutions
7. Boston University biomedical engineers win major grant for pursuit of the $1,000 Genome
8. Scientists win grants to develop $1,000 genome sequencing technology
9. In presence of fragrant cleaning products, air purifiers that emit ozone can dirty the air
10. W.M. Keck Foundation funds study of friendly microbes
11. WHO suspends Marburg work, appeals for new funds
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Federal grant funds research novel HIV therapy

(Date:9/16/2014)... have discovered the "molecular brakes" that time the generation ... mice. These "hair cells" translate sound waves into electrical ... interpreted as sounds. If the arrangement of the cells ... of the research will be published in The ... proteins Hey1 and Hey2 act as brakes to prevent ...
(Date:9/16/2014)... The meteorite impact that spelled doom for the dinosaurs ... flowering plants to a much greater extent than their ... researchers. The results are published in the journal ... a treasure trove of thousands of fossilized leaves of ... team was able to reconstruct the ecology of a ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... seafood, the options are many and so are some of the ... healthy? Is it safe? Is it endangered? While there are many ... an iPhone app a group of researchers have found a ... then it is likely to be healthy to eat too," said ...
... are more common than ever before. According to the ... Americans suffers from an allergy from milder forms ... allergies which can lead to anaphylactic shock. ... an allergic reaction, the treatment is too limited, says ...
... Boulder, Colo., USA Two Geology studies focus on ... view of alpine denudation and the other studying and ... include fossil microatolls and sea level; the potential rupture ... Northwest and British Columbia; paleoclimate; and the relationship between ...
Cached Biology News:Study finds healthy seafood comes from sustainable fish 2What sets allergies in motion? 2What sets allergies in motion? 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 2Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 4Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 5Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 6Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 7Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 8
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
(Date:9/16/2014)... University scientists who created a deicing film for radar ... a transparent coating for glass. , The new ... could keep glass surfaces from windshields to skyscrapers free ... radio frequencies (RF). , The technology was introduced ... Applied Materials and Interfaces . , The material ...
(Date:9/16/2014)...  The Council for Entrepreneurial Development (CED), the ... country, today released a mid-year update to its ... It showed that in the first half of ... in the technology, life science, advanced manufacturing and ... variety of sources. Significant investment in technology companies and ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Mylan Inc. (NYSE: MYL ),today announced that Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... and 200 mg., Lamotrigine Tablets are the generic ... approximately $1.97 billion,for the 12 months ending Sept. 30, ...
... Calif., Dec. 12 LUMEDX Corporation, the ... and imaging,solutions, introduces CardioManager Performance Management System(TM),cardiology ... operational,financial -- into accessible, actionable information. CardioManager,s,performance ... a,high-level view of data and the ability ...
... the FDA for the Fourth Genmab Antibody ... Collaboration with Roche., COPENHAGEN, December 12 Genmab ... application (IND) for a,Genmab antibody developed under the company,s ... Roche. Genentech and Roche are collaborating on,development of the ...
Cached Biology Technology:New Cardiology Software Helps Heart Centers Manage for Optimal Clinical Performance 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3